Evidence map›Paper›PMID 40093865›Full record

ArticleHealth services insights2025

Long-term Follow-up for Survivors of Childhood Cancer in Saudi Arabia: A Multicenter Cross-Sectional Study.

Fahad Alabbas, Ibrahim Alharbi, Naveed Ahmad, Walid Ballourah, Khalid Alnajashi, Ghaleb Elyamany, Nawaf Alkhayat, Yaser Borai, Omar Alsharif, Hasna Hamzi and 8 more

Abstract read
In one paragraph

Article in Health services insights, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Fahad AlabbasDepartment of Pediatrics Hematology, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.ORCID https://orcid.org/0000-0001-6910-1369
Ibrahim AlharbiDepartment of Pediatrics Hematology and Oncology, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia.
Naveed AhmadDepartment of Pediatrics Oncology, King Abdullah Specialist Children Hospital, Riyadh, Saudi Arabia.
Walid BallourahDepartment of Pediatrics Hematology/Oncology and BMT, Comprehensive Cancer Center, King Fahad Medical City, Riyadh, Saudi Arabia.
Khalid AlnajashiDepartment of Pediatrics Cardiology, Prince Sultan Cardiac Center, Riyadh, Saudi Arabia.
Ghaleb ElyamanyDepartment of Central Military Laboratory and Blood Bank, Prince Sultan Medical Military City, Riyadh, Saudi Arabia.
Nawaf AlkhayatDepartment of Pediatrics Oncology, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
Yaser BoraiDepartment of Pediatrics Oncology, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
Omar AlsharifDepartment of Pediatrics Oncology, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.ORCID https://orcid.org/0000-0002-7511-9538
Hasna HamziDepartment of Pediatrics Oncology, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
Amal Bin HasanDepartment of Pediatrics Oncology, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
Waleed IbrahimDepartment of Pediatrics Oncology, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
Luluah AlbahlalScientific Research Center, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.ORCID https://orcid.org/0000-0001-9918-2382
Sara AlnasserScientific Research Center, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.ORCID https://orcid.org/0000-0002-3270-6337
Sulaiman AlajlanDepartment of Pediatrics Hematology, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
Abdelrahman A AboushDepartment of Pediatrics Hematology/Oncology and BMT, Comprehensive Cancer Center, King Fahad Medical City, Riyadh, Saudi Arabia.
Reem Al-SudairyDepartment of Pediatrics Oncology, King Abdullah Specialist Children Hospital, Riyadh, Saudi Arabia.
Abdulrahman AlsultanDepartment of Pediatrics, College of Medicine, King Saud University, Riyadh, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: With the advancement of childhood cancer therapy, long-term survivors are on the rise. Reports on childhood cancer survivors in Saudi Arabia are scarce. This study aims to assess the spectrum and burden of long-term complications among survivors of childhood cancer in Saudi Arabia. Methods: This cross-sectional study, conducted at multiple cancer centers in Saudi Arabia, enrolled survivors who had been diagnosed with cancer before the age of 14 and had completed at least 5 years after completion of cancer therapy. The primary outcome was to estimate the prevalence of chronic health conditions (CHC) among these survivors. The secondary outcome was to assess the impact of primary cancer diagnosis and cancer therapies on the occurrence of CHC. Results: A total of 305 survivors met the inclusion criteria as of July 2022. Females were 165 participants. The median follow-up and age at evaluation were 8.5 and 14 years, respectively. Leukemia was the most common cancer type (49.3%), followed by lymphoma (16.7%) and solid tumors (15.7%). Chemotherapy was administered to 287 survivors. Radiotherapy and surgery were used in 29.2% and 22.3% of cases, respectively. Seventy-eight percent of participants experienced at least 1 CHC, with 31.1% and 14.2% having 2 and 3 CHC, respectively. A multivariate logistic regression identified significant association between CHC and solid tumors compared to hematological malignancies (OR 2.2; 95% CI: 1.1-4.3; Conclusion: The long-term complications of childhood cancer have revealed a prevalent concern. To optimize health outcomes, it is essential to implement well-structured and long-term follow-up tailored to risk profiles, utilize cost-effective screening methods, and promote prospective clinical research and establishment of a registry.

Indexed as

Childhood cancer survivorschronic health conditionslong-term

Identifiers

PMID40093865
PMCPMC11909668

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.